- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery company, announces today that its Annual General Meeting of Shareholders (the "Meeting") has appointed Mrs. Susan Swarte to the Executive Board and has appointed Mrs. Nancy de Ruiter to the Supervisory Board.
Mrs. Swarte has been appointed for a period of four years. Mrs. Swarte has over 16 years of experience in financial and strategic management and joined OctoPlus on 1 August 2009 as Chief Financial Officer.
Mrs. De Ruiter was appointed for a period of four years. Mrs. De Ruiter has a scientific background and has held several Supervisory Board positions. Mrs. De Ruiter currently indirectly holds 3.0% of OctoPlus' outstanding shares through ACEE B.V. but is independent within the meaning of the Dutch Corporate Governance.
Next to the above appointments, Mr. Hans Stellingsma has been reappointed as chairman of the Supervisory Board for a period of four years. Messrs. Philip Smith and Paul Toon have resigned from the Supervisory Board today.
The shareholders also approved all other agenda items of today's Meeting.
This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.
OctoPlus is a drug delivery company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.
The clinically most advanced product incorporating our technology is Biolex Therapeutics' lead product Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and is currently in Phase IIb clinical studies.
In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO.
For more information, please click here
+31 (71) 524 1071
Copyright © OctoPlusIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Nanoantenna lighting-rod effect produces fast optical switches October 24th, 2016
New nanomedicine approach aims to improve HIV drug therapies October 24th, 2016